Aqilion’s CEO Sarah Fredriksson participated at the Expert Insights session of the BioStock Investor Meeting. During the interview, she discussed the company’s recent deal with Merck and gave insights on dealmaking in the biotech world.
Watch the interview with Aqilion’s CEO Sarah Fredriksson below.
The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.